Post Essential Thrombocythaemia Myelofibrosis clinical trials

Explore recruiting post essential thrombocythaemia myelofibrosis clinical trials.

Recruiting post essential thrombocythaemia myelofibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Post Essential Thrombocythaemia Myelofibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)

Hungary, Czechia, Romania, Spain, Italy, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Germany, Czechia, Romania, Ireland, Austria, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), Or Post Essential Thrombocythemia MF (Post ET MF) Who Have a Suboptimal Response to Ruxolitinib

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

Greece, Italy, Germany, Spain, France, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, multi-center, Phase IV rollover protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with either panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462), and are judged by the investigator to benefit from continued treatment

Germany, Italy, Sweden, Poland

Therapeutic use (Phase IV) EU CTIS Study details

Post Essential Thrombocythaemia Myelofibrosis trials by city

Post Essential Thrombocythaemia Myelofibrosis in Toronto Post Essential Thrombocythaemia Myelofibrosis in Vancouver Post Essential Thrombocythaemia Myelofibrosis in Montreal Post Essential Thrombocythaemia Myelofibrosis in Calgary Post Essential Thrombocythaemia Myelofibrosis in Edmonton Post Essential Thrombocythaemia Myelofibrosis in Ottawa Post Essential Thrombocythaemia Myelofibrosis in Winnipeg Post Essential Thrombocythaemia Myelofibrosis in Quebec City Post Essential Thrombocythaemia Myelofibrosis in Hamilton Post Essential Thrombocythaemia Myelofibrosis in Kitchener Post Essential Thrombocythaemia Myelofibrosis in London Post Essential Thrombocythaemia Myelofibrosis in Halifax Post Essential Thrombocythaemia Myelofibrosis in New York Post Essential Thrombocythaemia Myelofibrosis in Los Angeles Post Essential Thrombocythaemia Myelofibrosis in Chicago Post Essential Thrombocythaemia Myelofibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease